Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,012 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab.
Ferraro E, Singh J, Patil S, Razavi P, Modi S, Chandarlapaty S, Barrio AV, Malani R, Mellinghoff IK, Boire A, Wen HY, Brogi E, Seidman AD, Norton L, Robson ME, Dang CT. Ferraro E, et al. Among authors: norton l. NPJ Breast Cancer. 2022 Mar 22;8(1):37. doi: 10.1038/s41523-022-00380-7. NPJ Breast Cancer. 2022. PMID: 35319017 Free PMC article.
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K. Kauff ND, et al. Among authors: norton l. N Engl J Med. 2002 May 23;346(21):1609-15. doi: 10.1056/NEJMoa020119. Epub 2002 May 20. N Engl J Med. 2002. PMID: 12023992 Free article.
Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer.
Modi S, Panageas KS, Duck ET, Bach A, Weinstock N, Dougherty J, Cramer L, Hudis C, Norton L, Seidman A. Modi S, et al. Among authors: norton l. J Clin Oncol. 2002 Sep 1;20(17):3665-73. doi: 10.1200/JCO.2002.08.057. J Clin Oncol. 2002. PMID: 12202668 Clinical Trial.
Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia.
Offit K, Levran O, Mullaney B, Mah K, Nafa K, Batish SD, Diotti R, Schneider H, Deffenbaugh A, Scholl T, Proud VK, Robson M, Norton L, Ellis N, Hanenberg H, Auerbach AD. Offit K, et al. Among authors: norton l. J Natl Cancer Inst. 2003 Oct 15;95(20):1548-51. doi: 10.1093/jnci/djg072. J Natl Cancer Inst. 2003. PMID: 14559878
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.
Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, Hudis C, Roberge D, Norton L, Bégin LR, Offit K, Foulkes WD. Robson ME, et al. Among authors: norton l. Breast Cancer Res. 2004;6(1):R8-R17. doi: 10.1186/bcr658. Epub 2003 Oct 24. Breast Cancer Res. 2004. PMID: 14680495 Free PMC article.
Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments.
Dang CT, Dannenberg AJ, Subbaramaiah K, Dickler MN, Moasser MM, Seidman AD, D'Andrea GM, Theodoulou M, Panageas KS, Norton L, Hudis CA. Dang CT, et al. Among authors: norton l. Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4062-7. doi: 10.1158/1078-0432.CCR-03-0463. Clin Cancer Res. 2004. PMID: 15217939 Clinical Trial.
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer.
Dang CT, D'Andrea GM, Moynahan ME, Dickler MN, Seidman AD, Fornier M, Robson ME, Theodoulou M, Lake D, Currie VE, Hurria A, Panageas KS, Norton L, Hudis CA. Dang CT, et al. Among authors: norton l. Clin Cancer Res. 2004 Sep 1;10(17):5754-61. doi: 10.1158/1078-0432.CCR-04-0634. Clin Cancer Res. 2004. PMID: 15355903 Clinical Trial.
1,012 results